BioSpace News Archive

The type II variation submitted is based on data from CheckMate -238, an ongoing phase 3, randomized double-blind study of Opdivo 3 mg/kg versus Yervoy (ipilimumab) 10 mg/kg in patients who have undergone complete resection of stage IIIb/c or stage IV melanoma, in which Opdivo met its primary endpoint of recurrence-free survival.

Mercator MedSystems announced completion of enrollment today in the company’s LIMBO-ATX designed to use Mercator’s proprietary Bullfrog micro-infusion catheter

Regen BioPharma announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board.

TELA Bio today announced that Greg Firestone has joined the company as VP of strategic customer relations and will be responsible for developing collaborative relationships.

Ozurdex is the first approved intravitreal injection for RVO in China.

Varian today announced it has named Terilyn Juarez Monroe as Chief People Officer, senior VP, Human Resources effective October 30, 2017.

The Company will host a conference call on Monday, November 6, 2017 at 4:30 p.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph Goldwasser, Chief Financial Officer.

CBT Pharma presented preclinical data which showed that CBT-502 efficiently inhibited binding of PD-L1 with no binding to PD-L2, CD28, ICOS or CTLA4.

Hildred Capital Partners announced that Hildred has entered into an agreement under which it will assume a major stake in Crown Laboratories.

NEOS Therapeutics today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma to acquire all of the outstanding shares of Neos for $10.25 per share in cash.